0000000000448272

AUTHOR

K Bork

showing 6 related works from this author

A germline mutation in the platelet-derived growth factor receptor beta gene may be implicated in hereditary progressive mucinous histiocytosis.

2020

DermatologyBiologymedicine.diseaseSkin DiseasesReceptor Platelet-Derived Growth Factor betaHistiocytosisGermline mutationChronic diseaseHereditary progressive mucinous histiocytosisChronic DiseaseCancer researchmedicinePlatelet-Derived Growth Factor Receptor BetaHumansPlatelet-Derived Growth Factor BetaReceptorGeneHistiocytosisGerm-Line Mutation
researchProduct

ALDEN, an Algorithm for Assessment of Drug Causality in Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: Comparison With Case–Control Analysis

2010

Epidermal necrolysis (EN)--either Stevens-Johnson syndrome (SJS) or toxic EN (TEN)--is a severe drug reaction. We constructed and evaluated a specific algorithm, algorithm of drug causality for EN (ALDEN), in order to improve the individual assessment of drug causality in EN. ALDEN causality scores were compared with those from the French pharmacovigilance method in 100 cases and the case-control results of the EuroSCAR study. Scores attributed by ALDEN segregated widely. ALDEN pointed to a "probable" or "very probable" causality in 69/100 cases as compared to 23/100 with the French method (P < 0.001). It scored "very unlikely" causality for 64% of medications vs. none with the French metho…

DrugTime FactorsDrug-Related Side Effects and Adverse Reactionsmedia_common.quotation_subjectRecurrenceEpidermal necrolysisPharmacovigilanceProduct Surveillance PostmarketingHumansMedicinePharmacology (medical)Drug reactionProbabilitymedia_commonPharmacologybusiness.industryReproducibility of ResultsStevens johnsonmedicine.diseaseCausalityToxic epidermal necrolysisEuropePharmaceutical PreparationsCase-Control StudiesStevens-Johnson SyndromeCase control analysisFrancebusinessAlgorithmAlgorithmsClinical Pharmacology &amp; Therapeutics
researchProduct

Regionale intraarterielle Chemotherapie mit Dacarbazin bei isolierten Lebermetastasen eines malignen Melanoms

2008

A 58-year-old woman underwent regional intra-arterial chemotherapy for hepatic metastases of a malignant melanoma, because at the time no other organ metastasis was demonstrable. Dacarbazine was injected as a bolus on five successive days, four weeks apart, after which there were several days of fever and the urinary melanogen test became positive. At first the patient clearly improved and was again able to walk. But four months after the start of treatment she died in a hepatic coma.

Isolated liverOncologymedicine.medical_specialtyChemotherapybusiness.industrymedicine.medical_treatmentDacarbazineMelanomaUrinary systemIntra arterial chemotherapyGeneral Medicinemedicine.diseaseGastroenterologyMetastasisBolus (medicine)Internal medicinemedicinebusinessmedicine.drugDMW - Deutsche Medizinische Wochenschrift
researchProduct

Acquired C1 inhibitor (C1-INH) deficiency type II. Replacement therapy with C1-INH and analysis of patients' C1-INH and anti-C1-INH autoantibodies

1989

Abstract The response of two patients with autoantibody-mediated C1-inhibitor (C1-INH) deficiency to replacement therapy with C1-INH was studied over a period of 3 d. In patient 1 an acute attack of angioedema was successfully managed by infusion of 1,000 U of C1-INH concentrate. C1-INH function returned to normal levels within 30 min, while CH50 and C4 peaked after 6-7 h and C1 hemolytic activity reached 50-60% of normal after 3 d. Immediately after the injection an increase in C1-INH-anti-C1-INH complexes was observed. Based on NH2-terminal sequence analysis of the patients' Mr 96,000 C1-INH, it is concluded that this fragment is generated after cleavage of C1-INH in its active site by on…

Molecular Sequence DataPharmacologyComplement C1 Inactivator ProteinsEpitopeC1-inhibitorAutoimmune DiseasesAntibody SpecificityImmunopathologyBlood plasmamedicineHumansheterocyclic compoundsAmino Acid SequenceAngioedemaInfusions IntravenousAutoantibodiesAngioedemabiologybusiness.industryAutoantibodyAntibody titerGeneral Medicinebiochemical phenomena metabolism and nutritionrespiratory systembacterial infections and mycosesrespiratory tract diseasesImmunologybiology.proteinmedicine.symptomAntibodybusinessResearch Article
researchProduct

Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor

2017

Prevenció; Atac d'angioedema; Inhibidor C1 Prevención; Ataque de angioedema; Inhibidor C1 Prevention; Angioedema attack; C1 inhibitor BACKGROUND: Hereditary angioedema is a disabling, potentially fatal condition caused by deficiency (type I) or dysfunction (type II) of the C1 inhibitor protein. In a phase 2 trial, the use of CSL830, a nanofiltered C1 inhibitor preparation that is suitable for subcutaneous injection, resulted in functional levels of C1 inhibitor activity that would be expected to provide effective prophylaxis of attacks. METHODS: We conducted an international, prospective, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase 3 trial to evaluate the …

Male:aminoácidos péptidos y proteínas::péptidos::serpinas::proteínas inactivadoras del complemento C1::proteína inhibidora del complemento C1 [COMPUESTOS QUÍMICOS Y DROGAS]0301 basic medicine:Otros calificadores::Otros calificadores::/prevención & control [Otros calificadores]Enzims proteolítics - InhibidorsSelf AdministrationSeverity of Illness Indexlaw.inventionC1-inhibitorSubcutaneous injection0302 clinical medicineRandomized controlled triallawCross-Over StudiesHereditary Angioedema Types I and IIbiologyEdema - PrevencióGeneral Medicine:Cardiovascular Diseases::Vascular Diseases::Angioedema::Angioedemas Hereditary [DISEASES]AnesthesiaHereditary angioedema:Other subheadings::Other subheadings::/administration & dosage [Other subheadings]Female:Amino Acids Peptides and Proteins::Peptides::Serpins::Complement C1 Inactivator Proteins::Complement C1 Inhibitor Protein [CHEMICALS AND DRUGS]medicine.symptomComplement C1 Inhibitor Protein:enfermedades cardiovasculares::enfermedades vasculares::angioedema::angioedemas hereditarios [ENFERMEDADES]AdultRiskmedicine.medical_specialtyInjections Subcutaneous:Aminoácidos Péptidos y Proteínas::Péptidos::Serpinas::Proteínas Inactivadoras del Complemento 1::Proteína Inhibidora del Complemento C1 [COMPUESTOS QUÍMICOS Y DROGAS]Placebo:Other subheadings::Other subheadings::/prevention & control [Other subheadings]03 medical and health sciencesDouble-Blind MethodInternal medicinemedicineHumans:Therapeutics::Drug Therapy::Drug Administration Routes::Injections::Injections Subcutaneous [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT]:Otros calificadores::Otros calificadores::/administración & dosificación [Otros calificadores]Dose-Response Relationship DrugAngioedemabusiness.industry:Terapéutica::Tratamiento Farmacológico::Vías de Administración de Medicamentos::Inyecciones::Inyecciones Subcutáneas [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]Injeccions hipodèrmiquesmedicine.diseaseCrossover studyClinical trial:terapéutica::farmacoterapia::vías de administración de medicamentos::inyecciones::inyecciones subcutáneas [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]030104 developmental biology030228 respiratory systembiology.proteinbusinessNew England Journal of Medicine
researchProduct

International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency

2016

BACKGROUND: The consensus documents published to date on hereditary angioedema with C1 inhibitor deficiency (C1-INH-HAE) have focused on adult patients. Many of the previous recommendations have not been adapted to pediatric patients. We intended to produce consensus recommendations for the diagnosis and management of pediatric patients with C1-INH-HAE.METHODS: During an expert panel meeting that took place during the 9th C1 Inhibitor Deficiency Workshop in Budapest, 2015 (www.haenet.hu), pediatric data were presented and discussed and a consensus was developed by voting.RESULTS: The symptoms of C1-INH-HAE often present in childhood. Differential diagnosis can be difficult as abdominal pain…

MaleAbdominal painPediatricsdiagnosisComorbidityDiseaseSeverity of Illness IndexEcallantide0302 clinical medicineRisk FactorsDiagnosisImmunology and Allergyheterocyclic compounds030212 general & internal medicineHereditary angioedemaPediatricHereditary Angioedema Types I and IIAge FactorsDisease ManagementCombined Modality TherapyImmunodeficienciesManagementHereditary angioedemaFemaleOriginal ArticleSymptom Assessmentmedicine.symptommanagementAlgorithmsmedicine.drugmedicine.medical_specialtyC1 inhibitor deficiencyImmunology03 medical and health sciencesMeta-Analysis as TopicmedicineHumansMucous MembraneAdult patientsbusiness.industryOriginal ArticlesC1 inhibitor deficiency; Diagnosis; Hereditary angioedema; Management; Pediatric; Immunology and Allergy; Immunologybacterial infections and mycosesmedicine.diseasehereditary angioedemarespiratory tract diseasesClinical trialpediatric030228 respiratory systemC1 inhibitor deficiencyDifferential diagnosisbusinessBiomarkers
researchProduct